Rapport Therapeutics, Inc. RAPP Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $78.06M+48.3% | $52.65M-79.1% | $251.36M+356% | $55.07M-4.4% | $57.6M+1.4% | ||
| $398.73M-8.9% | $437.89M+67.3% | $261.67M+27.4% | $205.38M-9.8% | $227.78M-8.3% | ||
| $58K— | $0— | —— | —— | $0— | ||
| $484.7M-2.8% | $498.56M-4.2% | $520.66M+92.7% | $270.24M-7.1% | $290.97M-6.1% | ||
| $2.52M-15.4% | $2.98M-4.5% | $3.12M-1.8% | $3.17M-6.8% | $3.4M-3.5% | ||
| $497.6M-2.9% | $512.43M-4.3% | $535.32M+87.5% | $285.5M-5.5% | $302.05M-4.1% | ||
| $6.56M+56.6% | $4.19M+29.5% | $3.24M+1.9% | $3.18M+48.5% | $2.14M+9.5% | ||
| $17.9M-6.0% | $19.05M+33.1% | $14.32M+20.5% | $11.88M+26.6% | $9.38M+7.0% | ||
| $26.09M-6.1% | $27.78M+17.2% | $23.71M+7.8% | $21.98M+35.6% | $16.22M+70.6% | ||
| $48K0.0% | $48K0.0% | $48K+29.7% | $37K0.0% | $37K0.0% | ||
| -$255.09M-8.4% | -$235.23M-16.8% | -$201.47M-15.4% | -$174.54M-18.1% | -$147.81M-19.4% | ||
| $471.51M-2.7% | $484.65M-5.3% | $511.62M+94.2% | $263.51M-7.8% | $285.84M-6.4% | ||
| $497.6M-2.9% | $512.43M-4.3% | $535.32M+87.5% | $285.5M-5.5% | $302.05M-4.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Rapport Therapeutics, Inc.'s total assets?
- Rapport Therapeutics, Inc. (RAPP) holds $497.6M in total assets, up 64.7% year over year.
- How much debt does Rapport Therapeutics, Inc. have?
- Rapport Therapeutics, Inc. carries $10.8M in total debt against $471.5M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Rapport Therapeutics, Inc. have?
- Rapport Therapeutics, Inc. holds $78.1M in cash and equivalents.
- Can Rapport Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 27.08 — current assets exceed current liabilities.
- Where does Rapport Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.